Abstract
Interleukin 5 (IL-5) is the key cytokine in an eosinophils life span: it supports eosinophilopoiesis and eosinophil differentiation, contributes to eosinophil migration, tissue localisation and function, and prevents eosinophil apoptosis. Given the likely role of eosinophils in chronic inflammatory diseases, a lot of research over the past decade was aimed at antagonising IL-5 function. It appears from recent studies that, although this can easily be achieved in vitro, blocking IL-5 function in vivo is much more difficult than originally anticipated. Here, we review the current status of IL-5 and IL-5 receptor research, with emphasis on strategies to interfere with IL-5 function.
Keywords: interleukin-5, eosinophilic diseases, eosinophil's life span, eosinophilopoiesis, eosinophil differentiation, inflammatory diseases
Current Drug Targets - Inflammation & Allergy
Title: Interleukin-5, Eosinophilic Diseases and Therapeutic Intervention
Volume: 2 Issue: 4
Author(s): Lennart Zabeau, Philippe Gevaert, Claus Bachert and Jan Tavernier
Affiliation:
Keywords: interleukin-5, eosinophilic diseases, eosinophil's life span, eosinophilopoiesis, eosinophil differentiation, inflammatory diseases
Abstract: Interleukin 5 (IL-5) is the key cytokine in an eosinophils life span: it supports eosinophilopoiesis and eosinophil differentiation, contributes to eosinophil migration, tissue localisation and function, and prevents eosinophil apoptosis. Given the likely role of eosinophils in chronic inflammatory diseases, a lot of research over the past decade was aimed at antagonising IL-5 function. It appears from recent studies that, although this can easily be achieved in vitro, blocking IL-5 function in vivo is much more difficult than originally anticipated. Here, we review the current status of IL-5 and IL-5 receptor research, with emphasis on strategies to interfere with IL-5 function.
Export Options
About this article
Cite this article as:
Zabeau Lennart, Gevaert Philippe, Bachert Claus and Tavernier Jan, Interleukin-5, Eosinophilic Diseases and Therapeutic Intervention, Current Drug Targets - Inflammation & Allergy 2003; 2 (4) . https://dx.doi.org/10.2174/1568010033484043
DOI https://dx.doi.org/10.2174/1568010033484043 |
Print ISSN 1568-010X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-010X |
Related Articles
-
Disease Modifying Approaches for Alzheimers Pathology
Current Pharmaceutical Design Treatment of Graves Hyperthyroidism with Thionamides-Derived Drugs: Review
Medicinal Chemistry Sigma-1 Receptors: Potential Targets for the Treatment of Substance Abuse
Current Pharmaceutical Design Gene Elements that Regulate Streptococcus pneumoniae Virulence and Immunity Evasion
Current Gene Therapy Editorial (Thematic Issue: Is The Female Heart Exposed To Cardiovascular Disease?)
Current Medicinal Chemistry Functional Domains of Aquaporin-1: Keys to Physiology, and Targets for Drug Discovery
Current Pharmaceutical Design IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design Intraocular Inflammation and Systemic Immune-Mediated Diseases
Current Immunology Reviews (Discontinued) Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment
Current Neuropharmacology Therapeutic Targeting of B Lymphocyte Stimulator (BLyS) in the Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Melatonin Role in Experimental Arthritis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Testosterone as Potential Effective Therapy in Treatment of Obesity in Men with Testosterone Deficiency: A Review
Current Diabetes Reviews The CX3C-Chemokine Fractalkine in Kidney Diseases
Mini-Reviews in Medicinal Chemistry Probing Cerebrovascular Alterations in Alzheimers Disease Using MRI: From Transgenic Models to Patients
Current Medical Imaging Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy
Current Pharmaceutical Design Pro-Inflammatory Gene Variants in Myocardial Infarction and Longevity: Implications for Pharmacogenomics
Current Pharmaceutical Design Recent Understanding of Leukocytapheresis (LCAP) for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Commentary: Perivascular Fat and Improved Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology Nanobiotechnology-based Drug Delivery in Brain Targeting
Current Pharmaceutical Biotechnology